A fully human monoclonal antibody directed against nerve growth factor (NGF) with potential analgesic activity.Upon administration, fulranumab binds to NGF, preventing its binding to and activation of the NGF receptors T rkA and p75NT R. Inhibition of the NGF pathway may prevent the perception of pain and may induce analgesia.NGF, a neurotrophic factor that plays a key role in neuropathic and inflammatory-induced pain, promotes hyperalgesia and allodynia.